Adherence by measurement technique
| Month | No. of participants | % of doses taken, median (IQR) | Tenofovir disoproxil fumarate/emtricitabine level, fmol/punch*; no. (%) of participants | |||||
|---|---|---|---|---|---|---|---|---|
| Self-reported 4-d recall | Pill count | Median (IQR) | ≤ 349 | 350–699 | 700–1249 | ≥ 1250 | ||
| 1 | 52 | 100 (100–100) | 100 (96.4–100) | 930 (746.5–1199) | 2 (4) | 7 (13) | 32 (62) | 11 (21) |
| 3 | 52 | 100 (100–100) | 98.7 (93.7–100) | 1341 (1062–1555.5) | 0 (0) | 4 (8) | 18 (35) | 30 (58) |
| 6 | 51 | 100 (100–100) | 98.9 (92.9–100) | 1432 (1068–1847) | 0 (0) | 4 (8) | 15 (29) | 32 (63) |
| 9 | 48 | 100 (100–100) | 98.9 (95.0–100) | 1392.5 (1141–1662.5) | 1 (2) | 3 (6) | 11 (23) | 33 (69) |
| 12 | 42 | 100 (95.0–100) | 98.0 (90.1–100) | 1191.5 (777–1527) | 2 (5) | 6 (14) | 15 (36) | 19 (45) |
Note: IQR = interquartile range.
↵* Levels of 349 fmol/punch or less, 350–699 fmol/punch, 700–1249 fmol/punch and 1250 fmol/punch or greater correspond to preexposure prophylaxis dosing on less than 2, 2–3, 4–6 and 7 days per week, respectively. (24)